Xenoglim-MP1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug concentrations. Xenoglim-MP1 is indicated for adults inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. It is essential to monitor glycemic parameters regularly and adjust therapy accordingly. Caution is advised in patients with hepatic, renal, or cardiovascular impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. This combination therapy should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise.